Please use this identifier to cite or link to this item:
Title: Ceftobiprole for the treatment of pneumonia
Author: Cillóniz, Catia
Dominedò, Cristina
Garcia Vidal, Carolina
Torres Martí, Antoni
Keywords: Pneumònia
Infeccions per pneumococs
Pneumococcal infections
Issue Date: 1-Jan-2019
Publisher: Sociedad Española de Quimioterapia
Abstract: Ceftobiprole is a fifth-generation cephalosporin with potent antimicrobial activity against Gram positive and Gram-negative bacteria. It has been approved in major European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Ceftobiprole is currently in a phase 3 clinical program for registration in the U.S. In 2015, it was designated as an infectious disease product qualified for the treatment of lung and skin infections by the FDA. The efficacy of ceftobiprole in pneumonia has been demonstrated in two-phase III clinical trials conducted in patients with CAP and HAP. The recommended dose in the adult with pneumonia is 500 mg every 8 h infused in 2 h; in case of renal failure, the regimen of administration must be adjusted according to the patient's renal function. It is not necessary to adjust the dose according to gender, age, body weight or liver failure. In case of hyperfiltration, an extension to 4 h infusion of the 500mg TID is required.
Note: Reproducció de document publicat a:
It is part of: Revista Española de Quimioterapia, 2019, vol. 32, supl. 3, p. 17-23
ISSN: 0214-3429
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
12474_5766842_revespquimioter-32-suppl-3-17.pdf507.7 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.